Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
American Journal of Therapeutics|May 11, 2004
The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomesNu He, Timi Edeki
American Journal of Therapeutics|September 1, 1996
Comparison of Plasma Protein Binding of Basic Drugs in Black and White IndividualsTimi Edeki, Betty Dillon-Moore, Nu He
European Journal of Clinical Pharmacology|April 9, 2002
Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomesNu He, Wen-Qi Zhang, Dolores Shockley, et al.
British Journal of Clinical Pharmacology|July 22, 2014
Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volumeTimi Edeki, Mirjana Kujacic, Helen Broadhurst, et al.
Pharmacology Research & Perspectives|October 31, 2015
Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjectsShampa Das, Jianguo Li, Jon Armstrong, et al.
Journal of Clinical Pharmacology|October 24, 2013
Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactamShampa Das, Jon Armstrong, David Mathews, et al.
Clinical Drug Investigation|December 10, 2015
A Randomized, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam in Healthy Chinese SubjectsJianguo Li, Maria Learoyd, Furong Qiu, et al.
Clinical and Experimental Pharmacology & Physiology|August 23, 2006
Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomesNu He, Hong-Guang Xie, Xavier Collins, et al.
The Mount Sinai Journal of Medicine, New York|June 8, 2006
Erythrocytosis in a scleroderma patientEric Mabo, Timi Edeki, Gloria E Westney, et al.
International Journal of Antimicrobial Agents|November 8, 2015
An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysisMaria Sunzel, Maria Learoyd, Jianguo Li, et al.
Pageof 3